Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,067 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,060
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 399
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Type 1 Diabetes132
- Rheumatoid Arthritis131
- Atopic Dermatitis122
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections105
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California498
- Maryland198
- Alabama178
- Florida151
- Arizona150
- Massachusetts118
- New York114
- Texas112
- Illinois84
- Colorado81
Recruiting studies6,067 total
- NCT04491721Enrolling by invitation
Follow-up study comparing two rituximab options in new DLBCL
This study follows people who already took part in an earlier Phase III trial to see how well two rituximab medicines work over time. It looks at outcomes like how long participants live and how long the disease stays under control, and may help confirm whether the biosimilar is comparable to the original.
BeijingAges 18–80 - NCT04508790RecruitingPhase 2
Leflunomide plus pomalidomide with dexamethasone for relapsed myeloma
This trial studies whether a combination of three medicines (leflunomide, pomalidomide, and dexamethasone) can better treat multiple myeloma that has come back or stopped responding. It may help people who are not good candidates for transplant and who have measurable disease.
Duarte, CaliforniaAges 18 years+ - NCT04512456Recruiting
Exercise training study for people with HIV and heart health
This study looks at how a structured exercise program affects the heart and blood flow in people living with HIV. It may help your care team understand who benefits most from exercise and how to do it safely.
Rio de Janeiro, Rio de JaneiroAges 30–50 - NCT04573140RecruitingPhase 1
RNA vaccine study for newly diagnosed adult and pediatric brain tumors
This Phase 1 trial studies an “RNA-lipid particle” vaccine given after surgery for certain newly diagnosed brain cancers (glioblastoma in adults, high-grade glioma in children/teens). The goal is to see whether the vaccine is safe and can train the immune system to fight the tumor.
Washington D.C., District of ColumbiaAges 4 years+ - NCT04506593Recruiting
GI Motility diagnosis registry for people with digestion movement problems
This trial is a registry, meaning it collects information about people being evaluated for problems with how the gut moves. It may help doctors better diagnose gastrointestinal motility disorders in the future.
Indianapolis, IndianaAges Any age - NCT04575883Recruiting
Bike interval training for teens with repaired heart defects
This study tests a structured “interval” bike exercise program to see if it’s safe and helpful for teens with certain repaired congenital heart conditions. It may help improve fitness while closely monitoring heart symptoms during training.
Edmonton, AlbertaAges 10–18 - NCT04571658Recruiting
NEPTUNE Match study linking you to possible kidney research trials
This study is an add-on process that uses information from the NEPTUNE kidney study to see whether you might be able to join other kidney research trials. It may help connect eligible people with appropriate new treatment studies when they become available.
Atlanta, GeorgiaAges 1–80 - NCT04517838Recruiting
Testing immune responses to anti-HER2 breast cancer treatments
This study looks at how your immune system reacts to anti-HER2 treatments in people with HER2-positive breast cancer. It may help doctors understand who responds best by studying immune signals in blood (and sometimes tissue) during or after treatment.
Jacksonville, FloridaAges 18 years+ - NCT04587687RecruitingPhase 2
Brentuximab plus bendamustine for relapsed follicular lymphoma
This Phase 2 trial studies the combination of brentuximab vedotin and bendamustine in people whose follicular lymphoma has come back or did not respond. It aims to shrink the lymphoma and improve outcomes after at least one prior treatment.
Sacramento, CaliforniaAges 18 years+ - NCT04545762RecruitingPhase 1
Anti-CD19 CAR-T for certain relapsed lymphoma
This Phase 1 study tests an anti-CD19 CAR-T cell treatment in adults with specific types of relapsed or treatment-resistant non-Hodgkin lymphoma. It may help by finding and attacking lymphoma cells that carry the CD19 marker, but it’s early-stage and eligibility is strict.
San Francisco, CaliforniaAges 18 years+ - NCT04469842RecruitingEarly Phase 1
Long-acting tacrolimus after lung transplant
This early-stage study tests a long-acting form of tacrolimus (a common anti-rejection medicine) soon after lung transplant. It aims to see if it can be used safely and effectively for people receiving lung transplants at Vanderbilt (VUMC).
Nashville, TennesseeAges 18 years+ - NCT04425421Recruiting
Treatment plan for children with Burkitt lymphoma
This trial uses a recommended treatment approach for children who have Burkitt lymphoma, a specific type of blood cancer. It may help by guiding care when the full standard treatment schedule can’t be followed for every child.
OuagadougouAges Up to 18 years - NCT04380740RecruitingPhase 2
Longer vs shorter abatacept doses to prevent graft-versus-host disease
This trial tests whether giving abatacept for a longer or shorter time can better prevent graft-versus-host disease (a common complication after a stem cell transplant). If you’re having a planned unrelated donor transplant, the results may help reduce the risk or severity of transplant-related immune problems.
Duarte, CaliforniaAges 2 years+ - NCT04405700Recruiting
Tracking birth outcomes and birth defects after delivery
This study follows pregnant people and their babies to better measure adverse outcomes and possible congenital (from birth) conditions. It may help improve how birth risks and birth defects are identified and recorded at the clinic.
EldoretAges Any age - NCT04477928Recruiting
Checking type 1 diabetes risk using routine child care
This study estimates the chance of developing type 1 diabetes in children by using information gathered during regular well-child visits. It may help identify children who could benefit from earlier monitoring.
Bemidji, MinnesotaAges birth–17 years - NCT04452305Recruiting
Frozen testicle tissue transplant to restore fertility
This study tests using previously frozen (cryopreserved) testicle cells or tissue to regrow testicular tissue. If you’ve had cancer treatment that can harm fertility, this may help restore natural fertility potential using your own tissue.
Pittsburgh, PennsylvaniaAges Any age - NCT04390009RecruitingEarly Phase 1
Whole-body PET scans in people with multiple sclerosis
This early study tests how whole-body PET-CT scans can be used in people with multiple sclerosis (and compares with healthy volunteers). It may help researchers understand what the scan can show in MS throughout the body.
Ladera Ranch, CaliforniaAges 25–55 - NCT04455906Recruiting
Study why some people with eczema get more severe
This study looks at why disease tends to be more severe in some people with atopic dermatitis (eczema), especially those with a specific genetic change in the IL-4 receptor (IL-4Ra). The results may help explain what drives flare-ups and could guide better treatments in the future.
Boston, MassachusettsAges 6–65 - NCT04483206RecruitingPhase 1
Personalized stem cell transplant for multiple myeloma
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
Atlanta, GeorgiaAges 18 years+ - NCT04459689Recruiting
COVID-19 study for people with primary immune deficiencies
This study looks at COVID-19 experiences in people who have a primary immune deficiency (a long-term immune problem) and who have had COVID-19. It may help researchers better understand how COVID-19 affects people with these conditions.
ParisAges birth+ - NCT04462978Recruiting
Food allergies in children
This study looks at a type of food allergy that is not caused by Immunoglobulin E (IgE), a protein involved in many allergic reactions. The goal is to better understand these non-IgE food allergies in children and how they affect them.
NaplesAges 1 day–14 years - NCT04476563Recruiting
Study liver injury from checkpoint cancer immunotherapy
This study looks at why some people develop liver inflammation after checkpoint inhibitor cancer treatment, called checkpoint inhibitor–induced liver injury (ChILI). It compares people with ChILI to similar cancer patients who are starting the same type of immunotherapy, to better understand and track these liver injury events.
NottinghamAges 18 years+ - NCT04421846Recruiting
Studying the causes of severe seizures and immune brain swelling
This study looks at what causes severe seizure episodes (“status epilepticus”) and a related immune condition that affects the brain (“dysimmune encephalitis”). The goal is to better understand the disease process, which may guide future care.
ParisAges 2 years+ - NCT04419584RecruitingPhase 2/Phase 3
Modified Qing-Ying decoction for children with eczema
This trial tests a traditional Chinese herbal formula (Modified Qing-Ying Decoction) for children ages 4 to 17 with moderate-to-severe eczema (atopic dermatitis). The study aims to see if this herbal treatment can improve skin dryness, redness, and itching, especially for those with dry, scaly patches.
Hong KongAges 4–17
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,067 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,241 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.